217 related articles for article (PubMed ID: 37663280)
1. Co-inhibition of adenosine 2b receptor and programmed death-ligand 1 promotes the recruitment and cytotoxicity of natural killer cells in oral squamous cell carcinoma.
Wang B; Wang T; Yang C; Nan Z; Ai D; Wang X; Wang H; Qu X; Wei F
PeerJ; 2023; 11():e15922. PubMed ID: 37663280
[TBL] [Abstract][Full Text] [Related]
2. PER2 binding to HSP90 enhances immune response against oral squamous cell carcinoma by inhibiting IKK/NF-κB pathway and PD-L1 expression.
Zhang Z; Sun D; Tang H; Ren J; Yin S; Yang K
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37914384
[TBL] [Abstract][Full Text] [Related]
3. Triptolide suppresses oral cancer cell PD-L1 expression in the interferon-γ-modulated microenvironment in vitro, in vivo, and in clinical patients.
Kuo CS; Yang CY; Lin CK; Lin GJ; Sytwu HK; Chen YW
Biomed Pharmacother; 2021 Jan; 133():111057. PubMed ID: 33378962
[TBL] [Abstract][Full Text] [Related]
4. AIM2 promotes irradiation resistance, migration ability and PD-L1 expression through STAT1/NF-κB activation in oral squamous cell carcinoma.
Chiu HW; Lee HL; Lee HH; Lu HW; Lin KY; Lin YF; Lin CH
J Transl Med; 2024 Jan; 22(1):13. PubMed ID: 38166970
[TBL] [Abstract][Full Text] [Related]
5. Candida albicans induces upregulation of programmed death ligand 1 in oral squamous cell carcinoma.
Wang X; Zhao W; Zhang W; Wu S; Yan Z
J Oral Pathol Med; 2022 May; 51(5):444-453. PubMed ID: 35362187
[TBL] [Abstract][Full Text] [Related]
6. PD-L1-Mediated Immunosuppression in Oral Squamous Cell Carcinoma: Relationship With Macrophage Infiltration and Epithelial to Mesenchymal Transition Markers.
Wu T; Tang C; Tao R; Yong X; Jiang Q; Feng C
Front Immunol; 2021; 12():693881. PubMed ID: 34552581
[TBL] [Abstract][Full Text] [Related]
7. A2b and A3 adenosine receptors may act as promotive and prognostic factors in oral squamous cell carcinoma.
Zeng L; Wang C; Wang Z; Xiong H; Zhang T; Chen W; Hu X; Su T
J Craniomaxillofac Surg; 2023; 51(7-8):508-515. PubMed ID: 37596174
[TBL] [Abstract][Full Text] [Related]
8. Identification of a Favorable Prognostic Subgroup in Oral Squamous Cell Carcinoma: Characterization of ITGB4/PD-L1
Ma SR; Liu JF; Jia R; Deng WW; Jia J
Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371594
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of programmed death-1 and its ligand, programmed death ligand-1 in oral squamous cell carcinoma with and without oral submucous fibrosis.
Quan H; Liu S; Shan Z; Liu Z; Chen T; Hu Y; Yao Z; Fang L
Arch Oral Biol; 2020 Nov; 119():104916. PubMed ID: 32977151
[TBL] [Abstract][Full Text] [Related]
10. APE1 facilitates PD-L1-mediated progression of laryngeal and hypopharyngeal squamous cell carcinoma.
Wang J; Lun L; Jiang X; Wang Y; Li X; Du G; Wang J
Int Immunopharmacol; 2021 Aug; 97():107675. PubMed ID: 33964809
[TBL] [Abstract][Full Text] [Related]
11. IL-33/ST2 signaling promotes constitutive and inductive PD-L1 expression and immune escape in oral squamous cell carcinoma.
Zhao M; He Y; Zhu N; Song Y; Hu Q; Wang Z; Ni Y; Ding L
Br J Cancer; 2023 Mar; 128(5):833-843. PubMed ID: 36463324
[TBL] [Abstract][Full Text] [Related]
12. Expression of programmed cell death-ligand 1 in oral squamous cell carcinoma and oral leukoplakia is associated with disease progress and CD8+ tumor-infiltrating lymphocytes.
Chen XJ; Tan YQ; Zhang N; He MJ; Zhou G
Pathol Res Pract; 2019 Jun; 215(6):152418. PubMed ID: 31027907
[TBL] [Abstract][Full Text] [Related]
13. Predictive factors in the treatment of oral squamous cell carcinoma using PD-1/PD-L1 inhibitors.
Gao A; Pan X; Yang X; Lin Z
Invest New Drugs; 2021 Aug; 39(4):1132-1138. PubMed ID: 33594603
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
15. The Concordant Disruption of B7/CD28 Immune Regulators Predicts the Prognosis of Oral Carcinomas.
Chang SR; Chou CH; Liu CJ; Lin YC; Tu HF; Chang KW; Lin SC
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983005
[TBL] [Abstract][Full Text] [Related]
16. The involvement of epidermal growth factor receptor/protein kinase B signaling in the tumor intrinsic PD-L1-induced malignant potential of oral squamous cell carcinoma.
Sasabe E; Tomomura A; Yamamoto T
J Oral Pathol Med; 2024 May; 53(5):310-320. PubMed ID: 38693616
[TBL] [Abstract][Full Text] [Related]
17. Guanylate binding protein 5 triggers NF-κB activation to foster radioresistance, metastatic progression and PD-L1 expression in oral squamous cell carcinoma.
Chiu HW; Lin CH; Lee HH; Lu HW; Lin YK; Lin YF; Lee HL
Clin Immunol; 2024 Feb; 259():109892. PubMed ID: 38185269
[TBL] [Abstract][Full Text] [Related]
18. CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma.
Zhang S; Yan Q; Wei S; Feng X; Xue M; Liu L; Cui J; Zhang Y
Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Aug; 132(2):202-209. PubMed ID: 34034998
[TBL] [Abstract][Full Text] [Related]
19. Clinical and Biological Significance of PD-L1 Expression Within the Tumor Microenvironment of Oral Squamous Cell Carcinoma.
Takahashi H; Sakakura K; Arisaka Y; Tokue A; Kaira K; Tada H; Higuchi T; Okamoto A; Tsushima Y; Chikamatsu K
Anticancer Res; 2019 Jun; 39(6):3039-3046. PubMed ID: 31177146
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin-induced HSF1-HSP90 axis enhances the expression of functional PD-L1 in oral squamous cell carcinoma.
Sasaya T; Kubo T; Murata K; Mizue Y; Sasaki K; Yanagawa J; Imagawa M; Kato H; Tsukahara T; Kanaseki T; Tamura Y; Miyazaki A; Hirohashi Y; Torigoe T
Cancer Med; 2023 Feb; 12(4):4605-4615. PubMed ID: 36200687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]